Market Overview

Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; William Blair Comments on Miss

Share:
Related MDVN
Benzinga's M&A Chatter for Monday August 24, 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib, a Potent PARP Inhibitor, From BioMarin
Medivation to Gain Global Rights to BioMarin's Talazoparib (Zacks)

Sales of Astellas prostate cancer drug Xtandi were reported at $82 million within the US earlier, bringing down shares of Medivation (NASDAQ: MDVN) Thursday morning.

An analyst at William Blair issued a note this morning highlighting the result for Xtandi as lower than the firm's estimates for both the United States and E.U. region. The William Blair analyst was looking for $85.2 million in Xtandi sales for the quarter.

Xtandi's sales in Europe were approximately $2.6 million for 2Q, nearly half of William Blair's $4.8 estimate.

Astellas guided sales of Xtandi for FY2013 for approximately $400 million versus the $459 million William Blair estimate.

Shares of Medivation dropped over 4 percent at the open, but have regained ground and are trading down about 1 percent at last check.

Latest Ratings for MDVN

DateFirmActionFromTo
Aug 2015JefferiesMaintainsHold
Jul 2015Stifel NicolausMaintainsBuy
May 2015CitigroupMaintainsBuy

View More Analyst Ratings for MDVN
View the Latest Analyst Ratings

Posted-In: Analyst Color News Analyst Ratings

 

Related Articles (MDVN)

Get Benzinga's Newsletters